Cancer News: Ovarian
Olaparib has been approved for maintenance ovarian cancer treatment by the FDA, for women in complete or partial response to platinum-based chemotherapy.
Fewer women with history of breast and ovarian cancer take a recommended genetic test. This may increase their risk for additional cancers in the future.
The U.S. FDA has approved bevacizumab for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
The PARP inhibitor niraparib improves primary and secondary endpoints in platinum-sensitive recurrent ovarian cancer. Survival was significantly improved.
The lack of regular exercise throughout adulthood is associated with an increased risk of developing and dying from ovarian cancer, a new analysis reveals.
Immunotherapy given directly after chemotherapy to ovarian cancer patients stimulated immune cells that can kill cancer cells, a new analysis reveals.
Olaparib (Lynparza) induced positive patient outcomes in relapsed ovarian cancer patients, especially of the BRCAm mutation.
Treating patients of low-grade serous carcinoma (LGSC) of the ovary or peritoneum with hormonal maintenance therapy improved progression-free survival.
An innovative study showed that there is a risk of a possible decreased fertility in ovarian cancer patients treated with radioactive iodine treatment.
UK’s regulators have recommended olaparib for adult patients with relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
According to the largest randomized trials in ovarian cancer, screening may reduce ovarian cancer mortality, as it can detect the disease sufficiently early.
Counseling before and after a genetic cancer screening helped BRCA 1/2-negative patients make informed decisions and deal with anxiety, a new research reveals.
Ovarian cancer patients who had previously taken birth control pills had improved progression-free survival according to a new study.
Beta-blockers proved to be beneficial for ovarian cancer patients as they doubled survival, showed a clinical study of 1,425 patients.
Intraperitoneal chemotherapy proved to be beneficial for women with advanced ovarian cancer, a new study showed.
Chemotherapy given before surgery to women with advanced ovarian cancer resulted in fewer side effects and a better quality of life, a new trial reveals.
A review of 700 BRCA-positive breast cancer cases showed that removing ovaries significantly reduces the risk of death, especially for BRCA1 (62% lower).
In a trial, a cancer vaccine has led to a significant drop in 3-year recurrence rate in advanced ovarian cancer patients, compared to treatment with surgery alone.
In a trial, immunotherapy kept the cancer away longer in patients with late-stage ovarian cancer, bringing personalized medicine one step closer to reality.
Women receiving bevacizumab in addition to standard chemotherapy for ovarian cancer extended overall survival vs receiving standard chemotherapy treatment alone.
Introducing the "Anderson Algorithm”, surgeons achieved complete removal of all visible tumors in ovarian cancer patients, resulting in improved survival rates.
Women who take hormone replacement therapy for menopause (even for a few years) may face an increased risk of ovarian cancer, according to a detailed analysis.
Olaparib gained European approval for the treatment of advanced BCRA-mutated ovarian cancer. It is the first "PARP inhibitor" for this type of cancer.
The US FDA approved bevacizumab for treatment of patients with platinum resistant, recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer.
Research has revealed that tea and citrus fruits and juices are associated with a reduced risk of ovarian cancer, after studying women aged 25-55 for 30 years.
Olaparib, a drug for the maintenance treatment of platinum sensitive relapsed BRCA-mutated ovarian cancer has received positive opinion from European regulators.
A new test may better diagnose ovarian cancer. The test will also help distinguish between benign and malignant tumors, and identify the type of malignant ones.
There are several things women can do to lower their risk of developing certain types of cancer and improve their chances for survival if they do develop one of them, according to the Society of Gynecologic Oncology (SGO).
Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented at the 2013 European Cancer Congress (ECC2013).
Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.